As the first treatment cleared by the FDA for Demodex blepharitis, an eye disease estimated to affect 25 million people in the U.S. alone, Tarsus Pharmaceuticals’ Xdemvy is pitting its might ...
the first and only FDA approved treatment for Demodex blepharitis (DB). Demodex blepharitis occurs when Demodex mites – the most common ectoparasites found on humans – overpopulate on the eyelids.